Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC

M MacManus; L Kirby; B Blyth; O Banks; OA Martin; MM Yeung; N Plumridge; M Shaw; F Hegi-Johnson; S Siva; D Ball; SQ Wong

Journal article

Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC

M MacManus, L Kirby, B Blyth, O Banks, OA Martin, MM Yeung, N Plumridge, M Shaw, F Hegi-Johnson, S Siva, D Ball, SQ Wong

Clinical and Translational Radiation Oncology | ELSEVIER IRELAND LTD | Published : 2023

DOI: 10.1016/j.ctro.2023.100682

Open access

Abstract

Background: The kinetics of circulating tumor DNA (ctDNA) release following commencement of radiotherapy or chemoradiotherapy may reflect early tumour cell killing. We hypothesised that an increase in ctDNA may be observed after the first fraction of radiotherapy and that this could have clinical significance. Materials and methods: ctDNA analysis was performed as part of a prospective, observational clinical biomarker study of non-small cell lung cancer (NSCLC) patients, treated with curative-intent radiotherapy or chemoradiotherapy. Blood was collected at predefined intervals before, during (including 24 h after fraction 1 of radiotherapy) and after radiotherapy/chemoradiotherapy. Mutation..

View full abstract

University of Melbourne Researchers

Michael MacManus Author

Benjamin Blyth Author

Fiona Hegi-Johnson Author

Shankar Siva Author

Related Projects (2)

PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOUR BIOMARKERS IN PATIENTS TREATED WITH CURATIVE-INTENT RADIOTHERAPY FOR NSCLC

More than 50% of cancer patients in Australia receive radiotherapy but many later die from distant metastases. This study of circulating bio..

Defining the plasma methylome to guide melanoma treatment.

This project aims to characterise circulating methylation patterns (chemical modifications to DNA) from the blood of melanoma patients. Thro..

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

This work was funded through a National Health and Medical Research Council (NHMRC) project grant (ID1104139) . S.Q.W is supported by an NHMRC investigator grant (#1194783) . F-H. J. is supported by the Peter Mac Foundation and the Victorian Cancer Agency. Clinical trial coordinator support was provided by a grant from the Cancer council of Victoria.